<div id="readability-page-1"><div><ul><li>Mesa Laboratories Inc reported quarterly adjusted earnings of 45 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 80 cents. The mean expectation of three analysts for the quarter was for earnings of 16 cents per share. Wall Street expected results to range from -2 cents to 25 cents per share.</li><li>Revenue rose 5% to $60.74 million from a year ago; analysts expected $60.73 million. </li><li>Mesa Laboratories Inc's reported EPS for the quarter was 45 cents​.</li><li>The company reported quarterly net income of $2.48 million.</li><li>Mesa Laboratories Inc shares had risen by 10.7% this quarter and lost 43.7% so far this year.</li></ul>FORECAST CHANGES<ul><li>The mean earnings estimate of analysts was unchanged in the last three months.​ </li><li>In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</li></ul>RECOMMENDATIONS<ul><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 1 &#34;strong buy&#34; or &#34;buy,&#34; 2 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34; The average consensus recommendation for the medical equipment, supplies &amp; distribution peer group is also &#34;buy&#34; </li><li>Wall Street's median 12-month price target for Mesa Laboratories Inc is $88.50, about 15.4% above its last closing price of $74.87</li></ul>This summary was machine generated from LSEG data November 6 at 11:36 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)<div><table><tbody><tr><td>QUARTER ENDING</td><td>ESTIMATE </td><td>ACTUAL</td><td>BEAT, MET, MISSED</td></tr><tr><td>Sep. 30 2025 </td><td>0.16</td><td>0.45</td><td>Beat</td></tr><tr><td>Jun. 30 2025 </td><td>0.44</td><td>0.85</td><td>Beat</td></tr><tr><td>Mar. 31 2025 </td><td>1.09</td><td>-1.31</td><td>Missed</td></tr><tr><td>Dec. 31 2024 </td><td>1.75</td><td>-0.26</td><td>Missed</td></tr></tbody></table></div></div></div>

MLAB

Mesa Laboratories Inc reported adjusted earnings of 45 cents per share for the quarter ended September 30, down from 80 cents a year ago. Revenue increased 5% to $60.74 million, slightly above analyst expectations. The company’s net income was $2.48 million. Despite a 10.7% rise in shares this quarter, they have fallen 43.7% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $88.50, 15.4% above the last closing price of $74.87.

Mesa Laboratories Inc reports results for the quarter ended September 30 - Earnings Summary